
    <!DOCTYPE html>
    <html lang="en">
    <head>
        <meta charset="UTF-8">
        <meta name="viewport" content="width=device-width, initial-scale=1.0">
        <link href="https://stackpath.bootstrapcdn.com/bootstrap/4.3.1/css/bootstrap.min.css" rel="stylesheet">
        <title>actelion with Google PaLM2-EN - AI responses about the company/brand</title>
        <meta name="description" content="actelion with Google PaLM2-EN. Check AI answers about companies and brands. Tested with various GPTs and Google AIs until now.">
    </head>
    <body>
    <div class="container">
    <h1>actelion: AI reply from Google PaLM2-EN</h1>
<p>AI type: Google PaLM2-EN</p>
<p>AI reply test date: 2023-12-12</p>
<h2>AI reply text</h2>
<p id='aitext'> Actelion Pharmaceuticals Ltd was a Swiss biopharmaceutical company headquartered in Allschwil, Switzerland. It was founded in 1997 by Jean-Paul Clozel, Peter Grogg, and Robert Cawston. The company focused on the discovery, development, and commercialization of innovative drugs for the treatment of rare diseases. Actelion's main products included Tracleer (bosentan) for the treatment of pulmonary arterial hypertension (PAH), Opsumit (macitentan) for the treatment of PAH, and Zavesca (miglustat) for the treatment of Gaucher disease. In 2017, Actelion was acquired by Johnson & Johnson for $30 billion.</p>
<h3>More about the AI reply:</h3>
<p><strong>Sentiment:</strong> </p>
<p><strong>Magnitude:</strong> </p>
<p><strong>Best sentiment sentence:</strong> </p>
<p><strong>Worst sentiment sentence:</strong> </p>
<div class='model-links'>
<p><a href='actelion_GPT4-DE.html'>GPT4-DE</a></p>
<p><a href='actelion_GPT3.5-EN.html'>GPT3.5-EN</a></p>
<p><a href='actelion_GPT3.5-DE.html'>GPT3.5-DE</a></p>
<p><a href='actelion_Google PaLM2-DE.html'>Google PaLM2-DE</a></p>
<p><a href='actelion_GPT4-EN.html'>GPT4-EN</a></p>
</div>
<p><a href='../index.html'>Home</a></p>

    </div>
    </body>
    </html>
    